Studies have shown that histone deacetylase (HDAC) inhibitors can stimulate LIFR, even reversing the suppression of LIFR by hypoxia and PTHrP, thereby inducing a dormant phenotype in breast cancer cells43. The gene discussed is HDAC9; the disease is breast cancer.